BMY Stock Forecast 2025-2026
Distance to BMY Price Targets
BMY Price Momentum
10 Quality Stocks Worth Considering Now
Researching Bristol-Myers (BMY) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BMY and similar high-potential opportunities.
Latest BMY Stock Price Targets & Analyst Predictions
Based on our analysis of 34 Wall Street analysts, BMY has a neutral consensus with a median price target of $60.00 (ranging from $36.00 to $70.00). The overall analyst rating is Buy (6.7/10). Currently trading at $49.23, the median forecast implies a 21.9% upside. This outlook is supported by 7 Buy, 18 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Akash Tewari at Jefferies, projecting a 42.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BMY Analyst Ratings
BMY Price Target Range
Latest BMY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BMY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 11, 2025 | UBS | Trung Huynh | Neutral | Maintains | $54.00 |
| Apr 8, 2025 | Goldman Sachs | Asad Haider | Neutral | Downgrade | $55.00 |
| Feb 7, 2025 | Wells Fargo | Mohit Bansal | Equal-Weight | Maintains | $62.00 |
| Feb 4, 2025 | Cantor Fitzgerald | Olivia Brayer | Neutral | Maintains | $55.00 |
| Jan 28, 2025 | Citigroup | Andrew Baum | Neutral | Maintains | $65.00 |
| Jan 8, 2025 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $65.00 |
| Dec 16, 2024 | Jefferies | Akash Tewari | Buy | Upgrade | $70.00 |
| Dec 10, 2024 | B of A Securities | Tim Anderson | Neutral | Reinstates | $63.00 |
| Nov 15, 2024 | Wolfe Research | Alexandria Hammond | Peer Perform | Initiates | $0.00 |
| Nov 12, 2024 | Leerink Partners | David Risinger | Outperform | Upgrade | $73.00 |
| Nov 12, 2024 | BMO Capital | Evan Seigerman | Market Perform | Maintains | $61.00 |
| Nov 12, 2024 | Morgan Stanley | Terence Flynn | Underweight | Maintains | $39.00 |
| Nov 12, 2024 | Citigroup | Andrew Baum | Neutral | Maintains | $60.00 |
| Nov 1, 2024 | BMO Capital | Evan Seigerman | Market Perform | Maintains | $57.00 |
| Oct 25, 2024 | Citigroup | Andrew Baum | Neutral | Downgrade | $55.00 |
| Oct 18, 2024 | Cantor Fitzgerald | Olivia Brayer | Neutral | Reiterates | $50.00 |
| Oct 17, 2024 | Bernstein | Market Perform | Initiates | $56.00 | |
| Oct 9, 2024 | UBS | Trung Huynh | Neutral | Maintains | $54.00 |
| Oct 7, 2024 | Barclays | Carter Gould | Underweight | Maintains | $43.00 |
| Oct 7, 2024 | TD Cowen | Steve Scala | Hold | Maintains | $59.00 |
Bristol-Myers Squibb Company (BMY) Competitors
The following stocks are similar to Bristol-Myers based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bristol-Myers Squibb Company (BMY) Financial Data
Bristol-Myers Squibb Company has a market capitalization of $100.17B with a P/E ratio of 11.5x. The company generates $48.30B in trailing twelve-month revenue with a -18.5% profit margin.
Revenue growth is +7.5% quarter-over-quarter, while maintaining an operating margin of +22.7% and return on equity of -38.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Bristol-Myers Squibb Company (BMY) Business Model
About Bristol-Myers Squibb Company
Develops innovative medicines for various diseases.
Bristol-Myers Squibb generates revenue primarily through the research, development, and sale of pharmaceutical products, particularly focusing on oncology, immunology, cardiovascular diseases, and fibrotic diseases. The company invests heavily in research and development and collaborates with academic institutions and research entities to pioneer new treatments, thereby enhancing its product pipeline and market offerings.
Founded in 1887 and headquartered in New York City, Bristol-Myers Squibb is a significant player in the global healthcare market. Its commitment to innovation, especially in immunotherapy for cancer treatment, positions the company as a leader in addressing unmet medical needs and shaping future healthcare landscapes.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
34,100
CEO
Dr. Christopher S. Boerner Ph.D.
Country
United States
IPO Year
1972
Website
www.bms.comBristol-Myers Squibb Company (BMY) Latest News & Analysis
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
2 days agoBristol Myers (BMY) is not expected to have the necessary factors for a potential earnings beat in its upcoming report. Investors should prepare for this outcome.
Bristol Myers may miss earnings expectations, signaling potential weakness in financial performance, which could negatively impact stock prices and investor sentiment.
Bristol Myers aims to improve its business with new drug sales, but the 2025 outlook is concerning. Investors are advised to hold off on action for now.
Bristol Myers' reliance on new drugs highlights potential growth, but a weak 2025 outlook raises concerns about future profitability and stock performance. Caution is advised.
Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics
1 day agoBristol Myers (BMY) financial projections for Q1 2025 include top and bottom-line estimates, along with key metrics for a comprehensive performance review.
Projections for Bristol Myers’ key metrics can indicate its financial health and performance trends, influencing stock valuation and investment decisions.
The FDA has updated the label for CAMZYOS® (mavacamten), reducing echocardiography monitoring requirements and contraindications, potentially enhancing its market appeal.
FDA's label update for CAMZYOS reduces monitoring requirements, potentially increasing its adoption and sales, positively impacting $BMY's revenue and stock performance.
Dividend stocks, particularly high-yield ones, are favored by investors for their substantial income and potential for significant total returns.
High-yield dividend stocks attract investors due to their income generation and potential for substantial total returns, impacting stock demand and market valuations.
Bristol Myers Squibb announced that its experimental heart disease drug failed to meet primary objectives in a late-stage clinical trial.
Bristol Myers Squibb's drug failure may impact its stock price, future revenue projections, and investor confidence, highlighting potential risks in its pipeline and overall market performance.
Frequently Asked Questions About BMY Stock
What is Bristol-Myers Squibb Company's (BMY) stock forecast for 2025?
Based on our analysis of 34 Wall Street analysts, Bristol-Myers Squibb Company (BMY) has a median price target of $60.00. The highest price target is $70.00 and the lowest is $36.00.
Is BMY stock a good investment in 2025?
According to current analyst ratings, BMY has 7 Buy ratings, 18 Hold ratings, and 1 Sell ratings. The stock is currently trading at $49.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BMY stock?
Wall Street analysts predict BMY stock could reach $60.00 in the next 12 months. This represents a 21.9% increase from the current price of $49.23. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bristol-Myers Squibb Company's business model?
Bristol-Myers Squibb generates revenue primarily through the research, development, and sale of pharmaceutical products, particularly focusing on oncology, immunology, cardiovascular diseases, and fibrotic diseases. The company invests heavily in research and development and collaborates with academic institutions and research entities to pioneer new treatments, thereby enhancing its product pipeline and market offerings.
What is the highest forecasted price for BMY Bristol-Myers Squibb Company?
The highest price target for BMY is $70.00 from Akash Tewari at Jefferies, which represents a 42.2% increase from the current price of $49.23.
What is the lowest forecasted price for BMY Bristol-Myers Squibb Company?
Price targets from Wall Street analysts for BMY are not currently available. The stock is trading at $49.23.
What is the overall BMY consensus from analysts for Bristol-Myers Squibb Company?
The overall analyst consensus for BMY is neutral. Out of 34 Wall Street analysts, 7 rate it as Buy, 18 as Hold, and 1 as Sell, with a median price target of $60.00.
How accurate are BMY stock price projections?
Stock price projections, including those for Bristol-Myers Squibb Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.